Internal Medicine, Gastroenterology · New York, NY
NPI
1760640999
Since 2008
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
1283 York Avenue, 9th Floor
New York, NY, 10021
Phone (212) 241-8140
Groups this clinician bills Medicare through
Medicare paid, 2024
$105K
4,349 services
Medicare patients, 2024
229
Average age 73
Drug cost, 2024
$4.5M
680 prescriptions
Company payments, 2025
$236K
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Dana J Lukin was code J1745 (injection, infliximab, excludes biosimilar, 10 mg), 1,800 times for 16 patients. In total Dana J Lukin billed 4,349 services in 42 codes, and Medicare paid $105K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-07-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 1,800 | 16 | $24.94 | $45K |
| 99214 Office E&M - Established | Facility | 142 | 89 | $83.97 | $12K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 111 | 72 | $14.99 | $1,664 |
| 96415 Chemotherapy Administration | Office | 52 | 16 | $25.98 | $1,351 |
| 96413 Chemotherapy Administration | Office | 41 | 17 | $121.03 | $4,962 |
| 45380 Lower GI Endoscopy - Other | Facility | 32 | 32 | $124.50 | $3,984 |
| 91065 Test - Miscellaneous | Facility | 29 | 28 | $8.44 | $245 |
| 99204 Office E&M - New | Facility | 22 | 22 | $105.30 | $2,317 |
| 99222 Hospital E&M - Initial | Facility | 20 | 20 | $120.01 | $2,400 |
| 45385 Colonoscopy - Lesion Removal | Facility | 16 | 15 | $247.21 | $3,955 |
| 99213 Office E&M - Established | Facility | 12 | 12 | $56.77 | $681 |
| 99214 Office E&M - Established | Office | 12 | 11 | $104.59 | $1,255 |
By year: 2022 $103K for 8,532 services; 2023 $108K for 9,948 services; 2024 $105K for 4,349 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 43 | 36 | $2.97 | $128 |
Medicare prescription drug claims, 2024
In 2024, the drug Dana J Lukin prescribed most often to Medicare patients was Stelara (Ustekinumab), with 116 prescriptions and refills. In total Dana J Lukin wrote 680 Medicare prescriptions that cost $4.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Stelara Ustekinumab | 116 | 151 | 20 | $3.1M |
| Mesalamine Generic | 61 | 133 | 17 | $42K |
| Omeprazole Generic | 47 | 87 | 12 | $597 |
| Famotidine Generic | 41 | 95 | 14 | $734 |
| Mesalamine Er Mesalamine | 38 | 72 | Under 11 | $5,085 |
| Rinvoq Upadacitinib | 31 | 31 | Under 11 | $225K |
| Humira(Cf) Pen Adalimumab | 26 | 26 | Under 11 | $300K |
| Skyrizi On-Body Risankizumab-Rzaa | 26 | 49 | 12 | $509K |
| Linzess Linaclotide | 18 | 22 | Under 11 | $11K |
| Creon Lipase/Protease/Amylase | 17 | 23 | Under 11 | $55K |
| Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine | 17 | 17 | Under 11 | $828 |
| Lialda Mesalamine | 16 | 20 | Under 11 | $18K |
| Trulance Plecanatide | 14 | 14 | Under 11 | $7,040 |
| Balsalazide Disodium Generic | 13 | 13 | Under 11 | $646 |
| Methotrexate Methotrexate Sodium | 11 | 11 | Under 11 | $184 |
Brand drugs: - claims; generic drugs: 358 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Dana J Lukin $236K ($236K in general payments such as food, travel and fees) from 12 companies. The largest payer was Abbvie Inc. with $112K.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 74 | $112K |
| Janssen Biotech, Inc. JNJ | 77 | $104K |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 3 | $10K |
| Pfizer Inc. PFE | 12 | $7,437 |
| Lilly USA, LLC LLY | 4 | $2,436 |
| Phathom Pharmaceuticals, Inc. PHAT | 1 | $125 |
| Celltrion USA Inc. 068270.KS | 2 | $78.52 |
| Novo Nordisk Inc NVO | 2 | $38.97 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 1 | $32.5 |
| Genzyme Corporation SNY | 1 | $28.94 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.